Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro - PubMed (original) (raw)
Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro
Claudia Di Serio et al. Cell Mol Neurobiol. 2005 Sep.
Abstract
1. Kynurenic (KYNA) and quinolinic (QUIN) acids are neuroactive tryptophan metabolites formed along the kynurenine pathway: the first is considered a non-competitive antagonist and the second an agonist of glutamate receptors of NMDA type. The affinity of these compounds for glutamate receptors is, however, relatively low and does not explain KYNA neuroprotective actions in models of post-ischemic brain damage. 2. We evaluated KYNA effects on the release of fibroblast growth factor (FGF)-1, a potent neurotrophic cytokine. Because KYNA exhibits a neuroprotective profile in vitro and in vivo, we anticipated that it could function as an autocrine/paracrine inducer of FGF-1 release. Studies were performed in several models of FGF-1 secretion (FGF-1 transfected NIH 3T3 cells exposed to heat shock, A375 melanoma cells exposed to serum starvation, growth factor deprived human endothelial cells). To our surprise, KYNA, at low concentration, inhibited FGF-1 release in all cellular models. QUIN, a compound having opposite effects on glutamate receptors, also reduced this release, but its potency was significantly lower than that of KYNA. 3. KYNA and QUIN also displayed a major stimulatory effect on the proliferation rate of mouse microglia and human glioblastoma cells, in vitro. 4. Our data suggest that minor changes of local KYNA concentration may modulate FGF-1 release, cell proliferation, and ultimately tissue damage in different pathological conditions.
Similar articles
- Kynurenic Acid Prevents Cytoskeletal Disorganization Induced by Quinolinic Acid in Mixed Cultures of Rat Striatum.
Pierozan P, Biasibetti-Brendler H, Schmitz F, Ferreira F, Pessoa-Pureur R, Wyse ATS. Pierozan P, et al. Mol Neurobiol. 2018 Jun;55(6):5111-5124. doi: 10.1007/s12035-017-0749-2. Epub 2017 Aug 24. Mol Neurobiol. 2018. PMID: 28840509 - Kynurenic acid attenuates NMDA-induced pial arteriolar dilation in newborn pigs.
Bari F, Nagy K, Guidetti P, Schwarcz R, Busija DW, Domoki F. Bari F, et al. Brain Res. 2006 Jan 19;1069(1):39-46. doi: 10.1016/j.brainres.2005.11.033. Epub 2006 Jan 4. Brain Res. 2006. PMID: 16388784 - In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum.
Guidetti P, Wu HQ, Schwarcz R. Guidetti P, et al. Exp Neurol. 2000 May;163(1):123-30. doi: 10.1006/exnr.1999.7284. Exp Neurol. 2000. PMID: 10785450 - Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.
Erhardt S, Olsson SK, Engberg G. Erhardt S, et al. CNS Drugs. 2009;23(2):91-101. doi: 10.2165/00023210-200923020-00001. CNS Drugs. 2009. PMID: 19173370 Review. - Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk A, Urbanska EM. Ostapiuk A, et al. CNS Neurosci Ther. 2022 Jan;28(1):19-35. doi: 10.1111/cns.13768. Epub 2021 Dec 3. CNS Neurosci Ther. 2022. PMID: 34862742 Free PMC article. Review.
Cited by
- The effect of kynurenic acid on the synthesis of selected cytokines by murine splenocytes - in vitro and ex vivo studies.
Małaczewska J, Siwicki AK, Wójcik RM, Turski WA, Kaczorek E. Małaczewska J, et al. Cent Eur J Immunol. 2016;41(1):39-46. doi: 10.5114/ceji.2016.58815. Epub 2016 Mar 24. Cent Eur J Immunol. 2016. PMID: 27095921 Free PMC article. - Effects of Kynurenic Acid on the Rat Aorta Ischemia-Reperfusion Model: Pharmacological Characterization and Proteomic Profiling.
Lima VSS, Mariano DOC, Vigerelli H, Janussi SC, Baptista TVL, Claudino MA, Pimenta DC, Sciani JM. Lima VSS, et al. Molecules. 2021 May 11;26(10):2845. doi: 10.3390/molecules26102845. Molecules. 2021. PMID: 34064778 Free PMC article. - The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia.
Cuartero MI, de la Parra J, García-Culebras A, Ballesteros I, Lizasoain I, Moro MÁ. Cuartero MI, et al. Curr Pharm Des. 2016;22(8):1060-73. doi: 10.2174/1381612822666151214125950. Curr Pharm Des. 2016. PMID: 25248805 Free PMC article. Review. - IDO/kynurenine pathway in cancer: possible therapeutic approaches.
Abd El-Fattah EE. Abd El-Fattah EE. J Transl Med. 2022 Aug 2;20(1):347. doi: 10.1186/s12967-022-03554-w. J Transl Med. 2022. PMID: 35918736 Free PMC article. Review. - Fibroblast Growth Factor 1-Transfected Adipose-Derived Mesenchymal Stem Cells Promote Angiogenic Proliferation.
Hoseini SJ, Ghazavi H, Forouzanfar F, Mashkani B, Ghorbani A, Mahdipour E, Ghasemi F, Sadeghnia HR, Ghayour-Mobarhan M. Hoseini SJ, et al. DNA Cell Biol. 2017 May;36(5):401-412. doi: 10.1089/dna.2016.3546. Epub 2017 Mar 10. DNA Cell Biol. 2017. PMID: 28281780 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources